Cellectis preps for groundbreaking US trials for an off-the-shelf CAR-T therapy
Cellectis is ramping up the first-ever US trial launches for an off-the-shelf CAR-T therapy.
The Paris-based biotech $CLLS, which has a sizable R&D group in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
